Deadline: 03-Nov-2025
Cure Parkinson’s is inviting applications for its Quarterly Research Grant Funding Programme, offering support for preclinical and clinical research aimed at slowing, stopping, or reversing Parkinson’s disease. The programme is open internationally to academics and commercial entities, with the expectation that commercial applications keep costs in line with academic rates.
For preclinical research, grants of up to £250,000 are available, prioritising projects likely to progress to clinical trials within five years. For clinical research, funding is available for trials and related sub-studies involving people with Parkinson’s. The focus is on finding disease-modifying therapies that can benefit those currently living with Parkinson’s, meaning projects must aim to prevent, slow, stop, or reverse disease progression rather than simply provide symptomatic relief or focus on basic science.
Eligible research includes clinical trials, supporting sub-studies, infrastructure projects, and preclinical studies with strong potential for clinical translation within five years. Stage 1 applications, submitted via email, should include the application form, Drug and Compound CV if applicable, and a Commercial Entity form for commercial applicants. Optional documents such as investigator CVs, budget breakdowns, and supplementary materials like preliminary data or trial protocols can also be provided. Following review, selected applicants will be invited to submit a Stage 2 application with additional required documents.
For more information, visit Cure Parkinson’s.
